Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies
CA 2451173 C · Owner: Bertino, Joseph · Inventors: May, Chad; Sadelain, Michel; Bertino, Joseph
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Recombinant lentiviral vectors having a region encoding a functional globin gene; and large portions of the beta-globin locus control regions which include DNase I hypersensitive sites HS2 HS3 and HS4 provides expression of , beta-globin when introduced into a mammal for example a human, in vivo. , Optionally the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies including beta-thalessemia and sickle-cell disease. For example hematopoietic , progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 1, 2002 and granted December 18, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 1, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 1, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.